January 6, 2023

American CryoStem Announces FDA Approval of IND to Commence Phase I Clinical Trial for Long COVID/Post-Acute Sequelae of SARS-CoV-2 (PASC)

EATONTOWN, NJ / ACCESSWIRE /January 6, 2022 / American CryoStem Corporation (OTC PINK: CRYO), a clinical-stage therapeutics company with a proprietary end-to-end core biotechnology platform of tissue-based cellular technologies that powers its clinical pipeline announced today that it has received U.S. Food and Drug Administration (FDA) approval to proceed with a Phase I Clinical Trial for the treatment of Long COVID/PASC.
December 22, 2022

American CryoStem Announces the Addition of Agustin Legido, MD, PhD, MBA to its Advisory Board

EATONTOWN, NJ December 22, 2022; American CryoStem Corporation (OTC: CRYO), a clinical-stage therapeutics company with a proprietary end-to-end core biotechnology platform of tissue-based cellular technologies powering its clinical pipeline, announced today that Agustin Legido, MD, PhD, MBA has joined its Scientific and Medical Advisory Board.
March 4, 2022

American CryoStem Announces Patient Treatment Status for its Phase I Clinical Trial for Post-Concussion Syndrome (PCS)

EATONTOWN, NJ / ACCESSWIRE / March 4, 2022 American CryoStem Corporation (OTC: CRYO) a clinical stage biotechnology company, global licensor, and a pioneer in autologous cellular processing and cellular therapies, announced today that it has reached the midway point of its ATCell™ autologous mesenchymal stem cell therapy for Phase I Clinical Trial for Post-concussion syndrome (PCS).
December 22, 2021

American CryoStem Announces Completion of Patient Recruitment for its Post-Concussion Syndrome (PCS) ATCELL™ Phase I Clinical Trial

EATONTOWN, NJ / ACCESSWIRE / December 22, 2021 / American CryoStem Corporation (OTC PINK: CRYO) a clinical-stage biotechnology company, global licensor, and a pioneer in autologous cellular processing and therapies announced today that its clinical study team has completed recruiting subjects for its Investigational New Drug (IND) Phase I Clinical Trial for Post-concussion syndrome. The singe site, multi-dosage blinded study is being conducted by BioSolutions Clinical Research Center, LLC
November 30, 2021

American CryoStem Completes Clinical Protocol Design for Long COVID Study

EATONTOWN, NJ November 30, 2021; American CryoStem Corporation (OTC: CRYO), a leading clinical-stage biotechnology developer of adipose-derived stem cell therapies today announced completion of its Phase I clinical protocol design for the treatment of Long COVID. American CryoStem anticipates that the protocol will be filed as an FDA Phase I IND in cooperation with a major US medical center in Q-1, 2022.
November 23, 2021

American CryoStem Announces the addition of John Schwartz, PhD to its Advisory Board

EATONTOWN, NJ November 23, 2021; American CryoStem Corporation (OTC: CRYO), a leading clinical-stage biotechnology developer of adipose tissue-based cellular technologies for Regenerative and Personalized Medicine announced today that it has added John “Jay” Schwartz, PhD to its Scientific and Medical Advisory Board.
November 16, 2021

American CryoStem to Study New Standardized Treatment Protocols for Wound Healing

EATONTOWN, NJ November 16, 2021; American CryoStem Corporation (OTC: CRYO), a clinical stage biotechnology company, global licensor and a pioneer in autologous cellular processing and therapies announced today that it has completed the development of a new standardized wound healing protocol utilizing its tissue based technologies with Advanced Regenerative Associates (Tinton Falls, NJ).
November 12, 2021

American CryoStem Enters into an Agreement to Exchange Shares held by ACS Global, Inc

EATONTOWN, NJ / ACCESSWIRE / November 12, 2021 / American CryoStem Corporation (OTC PINK:CRYO), a leading strategic cellular application developer, global licensor of patented adipose tissue-based technologies for the Regenerative and Personalized Medicine industries, today announced an agreement has been reached between the Company and ACS Global, Inc to exchange 20,000,000 million CRYO common shares currently held by ACS Global, Inc for 1,000,000 shares of preferred stock.
May 6, 2021

American CryoStem Executes LOI with Advanced Regenerative Associates to Conduct Wound Healing Clinical Study

American CryoStem Corporation (OTC PINK: CRYO) a clinical-stage biotechnology company, global licensor, and a pioneer in autologous cellular processing and therapies announced today, that it has signed a Letter of Intent (LOI) with Advanced Regenerative Associates, LLC (“ARA”) of Tinton Falls, NJ for the development of a cell-based wound covering treatment for non-healing wounds, skin ulcers, and limb ischemia associated with type II diabetes, burns, and other systemic conditions.